Skip to main navigation Skip to search Skip to main content

Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary

  • Grace K. Dy
  • , Ramaswamy Govindan
  • , Vamsidhar Velcheti
  • , Gerald S. Falchook
  • , Antoine Italiano
  • , Jürgen Wolf
  • , Adrian G. Sacher
  • , Toshiaki Takahashi
  • , Suresh S. Ramalingam
  • , Christophe Dooms
  • , Dong Wan Kim
  • , Alfredo Addeo
  • , Jayesh Desai
  • , Martin Schuler
  • , Pascale Tomasini
  • , David S. Hong
  • , Piro Lito
  • , Qui Tran
  • , Simon Jones
  • , Abraham Anderson
  • Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T. Li

Research output: Contribution to journal › Review article › peer-review

Abstract

What is this summary about? This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer. CodeBreaK 100 specifically looked at patients with a particular change(mutation) in the KRAS gene resulting in the mutated protein called KRAS G12C. The KRAS G12C mutation can lead to development and growth of lung cancer. Patients received a treatment called sotorasib, which has accelerated approval or full approval in over 50 countries for patients with non-small-cell lung cancer with the KRAS G12C mutation. The CodeBreaK 100 study looked at whether sotorasib is a safe and effective treatment for advanced non-small-cell lung cancer. Sotorasib is designed to specifically target and lock the mutated KRAS protein in the inactive state to treat non-small-cell lung cancer. What were the results? In total, 174 adults were treated with sotorasib. Treatment-related side effects were seen in 70% of patients and were severe in 21% of patients. The most common side effects included diarrhea, increased liver enzymes, nausea and tiredness. 70 (41%) patients responded to sotorasib and 144 (84%) patients had tumors that either remained stable or shrunk in size. 29 (41%) patients who responded to sotorasib responded for over 12 months. After 2 years, 9 patients with a response remained on sotorasib; there were no notable increases in tumor size or development of new tumors over this time. There were 5patients who received sotorasib for more than 2 years and continued to respond. Long-term benefit was seen for some patients. Patients also benefitted from treatment when the tumor expressed different amounts of a protein called PD-L1.In total, 33% of patients were still alive after 2 years. What do the results mean? Results show the long-term benefit of sotorasib therapy for people with advanced KRAS G12C-mutated non-small-cell lung cancer. Clinical Trial Registration: NCT03600883 (CodeBreaK 100) (ClinicalTrials.gov) </sec.

Original languageEnglish (US)
Pages (from-to)113-120
Number of pages8
JournalFuture Oncology
Volume20
Issue number3
DOIs
StatePublished - Jan 1 2024

Keywords

  • Clinical trials
  • Lung
  • Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary'. Together they form a unique fingerprint.

Cite this